According to the NCCN Clinical Practice Guidelines for Breast Cancer for the management of invasive breast cancer, pertuzumab plus trastuzumab plus docetaxel is a preferred systemic therapy regimen for recurrent unresectable or stage IV HER2+ breast cancer (category 1 recommendation). Pertuzumab plus trastuzumab plus paclitaxel is also listed as a preferred regimen (category 2A recommendation).
For additional information, refer to European Society of Medical Oncology (ESMO) Metastatic Breast Cancer Living Guidelines for the treatment of patients with HER2+ metastatic breast cancer.
Learn more about the treatment of HER2+ breast cancer.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani. Fast Five Quiz: HER2+ Breast Cancer - Medscape - Aug 23, 2022.
Comments